RBC Capital maintains Insulet at Outperform, raises price target to $180 from $160
RBC Capital maintained its Outperform rating on Insulet and raised its price target to $180 from $160, citing a 9.1% upside from the Nov 4 close of $165.02. Recent analyst price targets for Insulet range from $150 to $200.
How this was made

The 30-second read
Why it matters
Analyst price target increase signals confidence but lacks new operational data.
Market read
Analyst upgrade may modestly influence Insulet's stock price.
What to watch
Insulet's recent earnings and guidance remain unchanged.
Background
Insulet Corp. (ticker ISLE) designs and manufactures insulin infusion devices.
Market effects
May lift sentiment for diabetes device sector.
Limited to US healthcare equities.
Minimal
Counterpoint
Target raises can be premature if underlying fundamentals unchanged.
Key entities
- AnalystRBC Capital
Raised Insulet price target to $180.
